RI
BCRX icon

RTW Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

RTW Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,000
Closed -$431K – 40
2015
Q3 		$431K Buy
+2,000
New +$26.7K 0.13% 34

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

RTW Investments's BCRX Position: Q1 2018 in Review

RTW Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2018, closing a stake of 3,372,674 shares — an estimated $16.6M sold.

RTW Investments first reported a position in BCRX in Q4 2014 and held it in 13 quarters. The position peaked at $33.8M in Q2 2015. 103 funds tracked by Wall St. Rank hold BCRX as of Q1 2018.

  • RTW Investments reported no remaining BioCryst Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • RTW Investments sold 3,372,674 BioCryst Pharmaceuticals shares in Q1 2018, an estimated $16.6M.
  • RTW Investments first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 13 quarters.
  • RTW Investments's BioCryst Pharmaceuticals position peaked at $33.8M in Q2 2015.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2018.

Based on RTW Investments's 13F filing for Q1 2018, filed 14 May 2018.